{"id":2660,"date":"2020-01-13T12:47:22","date_gmt":"2020-01-13T11:47:22","guid":{"rendered":"https:\/\/www.cvs-avocats.com\/cornet-vincent-segurel-micropharm\/"},"modified":"2025-08-21T10:55:57","modified_gmt":"2025-08-21T08:55:57","slug":"cornet-vincent-segurel-micropharm","status":"publish","type":"post","link":"https:\/\/www.cvs-avocats.com\/fr\/cornet-vincent-segurel-micropharm\/","title":{"rendered":"Cornet Vincent S\u00e9gurel conseille le Laboratoire britannique MicroPharm Ltd"},"content":{"rendered":"<div class=\"section__body\">\n<article class=\"article-normal\">\n<div class=\"article__head\">\n<h2 class=\"article__title\">\n<\/h2><\/div>\n<div class=\"article__entry\">\n<p><span>Dans le cadre de cette acquisition, MicroPharm, laboratoire sp\u00e9cialis\u00e9 dans la fabrication\u00a0<\/span><span>d\u2019antis\u00e9rums notamment d\u2019origine ovine (ex, ViperaTAb\u00ae, EchiTAbG\u2122), indiqu\u00e9s dans le<\/span> <span>traitement des envenimations provoqu\u00e9es par les vip\u00e8res europ\u00e9ennes et africaines, a\u00a0<\/span><span>acquis la branche d\u2019activit\u00e9 de fabrication et de commercialisation de s\u00e9rums antivenimeux<\/span> <span>compos\u00e9s de fragments d\u2019immunoglobuline \u00e9quine (ViperFav \u00ae, BothroFav\u00ae, ScorpiFav\u00ae),\u00a0<\/span><span>exploit\u00e9e par Sanofi Pasteur et Sanofi Pasteur Europe, ainsi que des \u00e9l\u00e9ments d\u2019actifs<\/span> <span>incorporels dont notamment des droits de marque et des \u00e9l\u00e9ments de savoir-faire industriel.\u00a0<\/span><\/p>\n<p><span>Selon Ian Cameron (Chief Executive Officer, MicroPharm) : \u00ab L\u2019acquisition de ces produits\u00a0<\/span><span>est une nouvelle \u00e9tape du d\u00e9veloppement de MicroPharm et du positionnement de<\/span> <span>l\u2019entreprise comme un des leaders sur le march\u00e9 pour la fourniture d\u2019antivenins de haute\u00a0<\/span><span>qualit\u00e9 \u00bb.<\/span> \u00a0<\/p>\n<p><span>L\u2019\u00e9quipe de Cornet Vincent S\u00e9gurel \u00e9tait dirig\u00e9e par Fran\u00e7ois Herpe, Associ\u00e9 IP et Adrien\u00a0<\/span><span>Debr\u00e9, Associ\u00e9 M&amp;A, assist\u00e9s par Alfred Lortat-Jacob, Associ\u00e9 Fiscal, et dans leurs \u00e9quipes<\/span> <span>par Lucile Quentel, Linda Far\u00e8s et Philippe Guinot.<\/span><\/p>\n<\/p><\/div>\n<\/article><\/div>\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dans le cadre de cette acquisition, MicroPharm, laboratoire sp\u00e9cialis\u00e9 dans la fabrication\u00a0d\u2019antis\u00e9rums notamment d\u2019origine ovine (ex, ViperaTAb\u00ae, EchiTAbG\u2122), indiqu\u00e9s dans le traitement des envenimations provoqu\u00e9es par les vip\u00e8res europ\u00e9ennes et africaines, a\u00a0acquis la branche d\u2019activit\u00e9 de fabrication et de commercialisation de s\u00e9rums antivenimeux compos\u00e9s de fragments d\u2019immunoglobuline \u00e9quine (ViperFav \u00ae, BothroFav\u00ae, ScorpiFav\u00ae),\u00a0exploit\u00e9e par Sanofi Pasteur [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":2661,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"footnotes":""},"categories":[16],"tags":[],"class_list":["post-2660","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communique"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/posts\/2660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/comments?post=2660"}],"version-history":[{"count":0,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/posts\/2660\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/media\/2661"}],"wp:attachment":[{"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/media?parent=2660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/categories?post=2660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/tags?post=2660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}